CA
DYN icon

Clearstead Advisors’s Dyne Therapeutics DYN Stock Holding History

Clearstead Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334 Buy
+15
New +$279 ﹤0.01% 3045
2025
Q4 		– Sell
-37
Closed -$469 – 2892
2025
Q3 		$469 Buy
+37
New +$422 ﹤0.01% 2743

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Clearstead Advisors's DYN Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 15 shares worth $334. The stake represents ﹤0.01% of the portfolio and ranks #3045 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in DYN as recently as Q3 2025.

Clearstead Advisors first reported a position in DYN in Q3 2025 and has held it in 2 quarters since. The position peaked at $469 in Q3 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Clearstead Advisors held 15 shares of Dyne Therapeutics worth $334 as of Q2 2026.
  • Dyne Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3045 holding.
  • Clearstead Advisors first reported a position in Dyne Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's Dyne Therapeutics position peaked at $469 in Q3 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.